News Sentiment

CRL sentiment intelligence

Charles River Laboratories news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 48 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Diagnostics & Research Read-through group
Latest close 233.41 Week of 10 Jul 2026
Weighted tone 60/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+1.2% over one week, +24.5% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call

Market Reaction

Balanced read

69/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 1.2% Price digesting
Trend fit Trend inactive 24.5% over four weeks
Fair value 23.1% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 24
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 48
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Ad Hoc News 8
Market source 7
simplywall.st 5
Stock Titan 4
TradingView 4
MarketWatch 3
MT Newswires 2
Moomoo 2

Event Lens

What the news is about

Classified themes
Market update 24
Analyst action 10
Earnings 6
Deals and strategy 4
Macro sensitivity 3
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 48
BioSpace Direct company coverage

Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call

Charles River Laboratories International, Inc. (NYSE: CRL) will announce its second-quarter 2026 financial results on Wednesday, August 5th, before the market opens. Following the release, the company will host a conference call on the same day at 9:00 a.m. ET to discuss the resu

Tone
Neutral 50/100
Event
Earnings
Published
16 Jul 2026 07:45
Source
BioSpace
Stock Titan Direct company coverage

Charles River investors will get Q2 results before market open Aug. 5

Charles River Laboratories International, Inc. (NYSE: CRL) is scheduled to release its second-quarter 2026 financial results on Wednesday, August 5th, before the market opens. The company will also host a conference call at 9:00 a.m. ET on the same day to discuss these results. I

Tone
Neutral 50/100
Event
Earnings
Published
15 Jul 2026 12:03
Source
Stock Titan
GlobeNewswire Direct company coverage

Cell-Based Assay Services for Preclinical Use Only Global Market Report 2026 Released — Profiles Charles River, Labcorp, Eurofins and Evotec

The global market for Cell-Based Assay Services for Preclinical Use Only is projected to grow from $4.47 billion in 2025 to $12.93 billion by 2035, driven by demand for drug discovery and personalized medicine. The report highlights cytotoxicity assays and plate-based luminometry

Tone
Positive 86/100
Event
Macro sensitivity
Published
15 Jul 2026 05:25
Source
GlobeNewswire
TradingView Direct company coverage

CRL5145816 Bond Risk Profile

This article provides a risk profile for the CRL5145816 bond issued by Charles River Laboratories International, Inc., with a 4.0% coupon and maturing on March 15, 2031. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issu

Tone
Neutral 50/100
Event
Balance sheet
Published
14 Jul 2026 09:38
Source
TradingView
MarketWatch Direct company coverage

Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors

Shares of Charles River Laboratories International Inc. (CRL) fell 1.57% during Monday's trading session, closing at $229.75. This underperformance occurred on a day when the broader stock market, represented by the S&P 500 and Dow Jones Industrial Average, also experienced decli

Tone
Negative 38/100
Event
Market update
Published
13 Jul 2026 17:16
Source
MarketWatch
TradingView Direct company coverage

Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $237.79, Implies 2% Upside

Analysts have raised the average 12-month price target for Charles River Laboratories International, Inc. (CRL) stock from $234.64 to $237.79, based on estimates from 14 analysts. This updated target suggests a potential 2% upside from the July 10 closing price. The consensus rat

Tone
Positive 71/100
Event
Analyst action
Published
13 Jul 2026 16:20
Source
TradingView
Contract Pharma Direct company coverage

Charles River to Provide GMP NGS Services to Arovella

Charles River Laboratories International Inc. has partnered with Arovella Therapeutics Ltd to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. This collaboration will support Arovella in developing its Invariant Natura

Tone
Positive 72/100
Event
Market update
Published
13 Jul 2026 15:38
Source
Contract Pharma
Moomoo Direct company coverage

Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating

Baird has raised its price target for Charles River Laboratories International (CRL) to $255 from $213, while reiterating an Outperform rating on the stock. This adjustment reflects Baird's continued positive outlook on the company's financial prospects and market position.

Tone
Positive 72/100
Event
Analyst action
Published
13 Jul 2026 15:07
Source
Moomoo
TradingView Direct company coverage

Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $235.64, Implies 1% Upside

The average 12-month price target for Charles River Laboratories International, Inc. (CRL) stock has been raised to $235.64 from $232.5 by 14 analysts, implying a 1% potential upside from its closing price on July 10. The consensus rating among 20 analysts remains "Buy," with a b

Tone
Neutral 50/100
Event
Analyst action
Published
13 Jul 2026 13:20
Source
TradingView
Stock Titan Direct company coverage

How Charles River’s gene sequencing work supports ALA-101 cancer cell therapy trials

Charles River Laboratories (NYSE: CRL) announced a collaboration with Arovella Therapeutics (ASX: ALA) to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services. This partnership will support Arovella's development of its ALA-101 iNKT cell therapy pla

Tone
Positive 87/100
Event
Deals and strategy
Published
13 Jul 2026 12:03
Source
Stock Titan
marketscreener.com Direct company coverage

Charles River Laboratories to Provide Cell Sequencing Services to Arovella Therapeutics

Charles River Laboratories will provide cell sequencing services to Arovella Therapeutics, supporting the latter's efforts to develop alternative cancer treatments. This collaboration aims to accelerate progress in therapeutic approaches by leveraging Charles River's expertise in

Tone
Positive 67/100
Event
Market update
Published
13 Jul 2026 10:36
Source
marketscreener.com
Simply Wall Street Direct company coverage

Charles River Laboratories International (CRL) Expands AI Pathology Platform, Is The Valuation Upside Already Priced In?

Charles River Laboratories International (CRL) has expanded its AI-enabled digital pathology platform, coinciding with the stock reaching a 52-week high and attracting investor attention. While a popular narrative suggests the company is 25.6% undervalued with a fair value of $31

Tone
Neutral 50/100
Event
Market update
Published
12 Jul 2026 20:37
Source
Simply Wall Street
Investing.com Nigeria Direct company coverage

Charles River Laboratories stock hits 52-week high at $236.67 By Investing.com

Charles River Laboratories International Inc. (CRL) stock has reached a new 52-week high of $236.67, with a market capitalization of $11.36 billion. This significant increase of 47.31% over the past year reflects strong investor confidence despite the stock appearing overvalued a

Tone
Positive 74/100
Event
Market update
Published
10 Jul 2026 15:07
Source
Investing.com Nigeria
Investing.com South Africa Direct company coverage

Charles River Laboratories stock hits 52-week high at $236.67

Charles River Laboratories (CRL) stock reached a new 52-week high of $236.67, with shares trading at $237.85, reflecting a significant 47.31% increase over the past year. This achievement is driven by robust performance and investor confidence, supported by strategic expansions i

Tone
Positive 77/100
Event
Market update
Published
10 Jul 2026 15:07
Source
Investing.com South Africa
MarketWatch Direct company coverage

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day

Charles River Laboratories International Inc. (CRL) stock rose 4.30% to $233.60 on Thursday, outperforming the broader market. This strong performance ended a two-day losing streak for the company's stock. The S&P 500 Index also saw gains, rising 0.81%, while the Dow Jones Indust

Tone
Positive 73/100
Event
Market update
Published
09 Jul 2026 20:30
Source
MarketWatch
The Globe and Mail Direct company coverage

Wall Street Analysts Are Bullish on Top Healthcare Picks

Wall Street analysts are showing bullish sentiment towards two healthcare companies: Harmony Biosciences Holdings (HRMY) and Charles River Labs (CRL). Mizuho Securities reiterated a Buy rating for Harmony Biosciences with a $50 price target, while Citi maintained a Buy rating for

Tone
Positive 80/100
Event
Analyst action
Published
09 Jul 2026 16:12
Source
The Globe and Mail
TradingView Direct company coverage

Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $226.79, Implies 1% Upside

Analysts have raised the average 12-month price target for Charles River Laboratories International, Inc. (CRL) stock to $226.79, up from $223.93. This new target implies approximately 1% potential upside based on the July 8 closing price, with individual forecasts ranging from $

Tone
Positive 67/100
Event
Analyst action
Published
09 Jul 2026 13:20
Source
TradingView
Ad-hoc-news.de Direct company coverage

Charles River Laboratories highlights its role in drug development. Steady operations underpin the s

Charles River Laboratories is a crucial contract research organization supporting the biotech and pharma industries from early discovery through preclinical development. The company's services, which include in vivo models, in vitro assays, and specialized safety studies, are vit

Tone
Positive 71/100
Event
Deals and strategy
Published
09 Jul 2026 08:26
Source
Ad-hoc-news.de
Trefis Direct company coverage

Charles River Laboratories International Stock Surges 27%, With A 9-Day Winning Spree

The article reports that Charles River Laboratories International stock has surged by 27%, marking a 9-day winning spree. No further details about the reasons for this surge or financial specifics are provided. The content primarily consists of a headline and website navigational

Tone
Positive 92/100
Event
Market update
Published
08 Jul 2026 22:37
Source
Trefis